| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | E David Crawford | |
| Zinelabidine Abouelfadel | |||
| P2860 | cites work | Adverse events associated with hormonal therapy for prostate cancer | Q24548201 |
| Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists | Q24633115 | ||
| Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function | Q28140656 | ||
| Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy | Q28144733 | ||
| GnRH agonists, antagonists, and assisted conception | Q28204206 | ||
| Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy | Q28258997 | ||
| Reimbursement issues with hormonal therapies for prostate cancer. | Q38466199 | ||
| Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. | Q39538175 | ||
| Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer | Q39727032 | ||
| Role of androgens in prostatic cancer. | Q40562425 | ||
| Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer | Q40970843 | ||
| Anti-androgens in the treatment of prostate cancer. | Q41031397 | ||
| A controlled trial of leuprolide with and without flutamide in prostatic carcinoma | Q41261975 | ||
| Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies | Q42206917 | ||
| Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study | Q43513296 | ||
| Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects | Q43678864 | ||
| A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer | Q43801246 | ||
| A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer | Q43931585 | ||
| Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. | Q44018378 | ||
| Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? | Q44052345 | ||
| Leuprorelin acetate granulomas: recurrent subcutaneous nodules mimicking metastatic deposits at injection sites. | Q44073674 | ||
| A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer | Q44108671 | ||
| Patients' choice of treatment in stage D prostate cancer | Q44244446 | ||
| A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer | Q44261957 | ||
| The use of flutamide as a single antiandrogen treatment for hormone‐refractory prostate cancer | Q44655027 | ||
| Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy | Q44660551 | ||
| Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection | Q45256738 | ||
| Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. | Q45930559 | ||
| Formulation study of leuprorelin acetate to improve clinical performance | Q46056581 | ||
| Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone | Q46478008 | ||
| Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study | Q46654015 | ||
| Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy | Q46875718 | ||
| A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer | Q46890166 | ||
| Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer | Q46974515 | ||
| An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate | Q47615746 | ||
| Isolation and properties of the FSH and LH-releasing hormone | Q47753713 | ||
| Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. | Q48522432 | ||
| Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer | Q48564998 | ||
| Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antatonist properties | Q48619634 | ||
| Biphasic regulation of the gonadotropin-releasing hormone receptor by receptor microaggregation and intracellular Ca2+ levels | Q48690894 | ||
| The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy | Q50249635 | ||
| Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate | Q73401217 | ||
| Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer | Q73737981 | ||
| Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration | Q73747740 | ||
| Therapeutic effects of leuprorelin microspheres in prostate cancer | Q73850250 | ||
| Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma | Q73978031 | ||
| Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats | Q74117283 | ||
| Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer | Q74293705 | ||
| Early effects of castration on the vascular system of the rat ventral prostate gland | Q74657635 | ||
| Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy | Q75435996 | ||
| Orchidectomy and oestrogen therapy revisited | Q77686111 | ||
| Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome | Q80017670 | ||
| Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer | Q80058781 | ||
| [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer] | Q80085868 | ||
| Cognitive effects of hormonal treatment for prostate cancer | Q80086220 | ||
| Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up | Q80152364 | ||
| Early hormonal therapy for prostate cancer: the good, the bad, and the ugly | Q80297055 | ||
| Gonadotropin-releasing hormone antagonist in the management of prostate cancer | Q80297643 | ||
| Experimental use of GnRH antagonists as second-line hormonal therapy | Q80297654 | ||
| A multidisciplinary approach to the management of hormone-refractory prostate cancer | Q80297756 | ||
| The evolution of hormonal therapy for prostatic carcinoma | Q80298007 | ||
| Flare Associated with LHRH-Agonist Therapy | Q80298013 | ||
| Basic science of hormonal therapy for prostate cancer | Q80298017 | ||
| New paradigms for advanced prostate cancer | Q80442445 | ||
| Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen | Q81261881 | ||
| Risk of fracture after androgen deprivation for prostate cancer | Q81264327 | ||
| II. The Present Position of the Surgery of the Hypertrophied Prostate | Q81271517 | ||
| Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer | Q81272515 | ||
| Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 | Q83170866 | ||
| Pituitary irradiation in prostatic carcinoma. | Q51356622 | ||
| The evolving definition of advanced prostate cancer. | Q51933129 | ||
| Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. | Q52107033 | ||
| [John Hunter (1728-1793): founder of scientific surgery and precursor of urology]. | Q52788452 | ||
| Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. | Q53906174 | ||
| Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial | Q56804990 | ||
| I. The Results of Double Castration in Hypertrophy of the Prostate | Q58760014 | ||
| Advanced prostatic carcinoma Flutamide therapy after conventional endocrine treatment | Q66951580 | ||
| Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients | Q67282774 | ||
| Plasma testosterone levels in patients with prostatic carcinoma before and after treatment | Q69841844 | ||
| Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma | Q69873360 | ||
| Ketoconazole: A Novel and Rapid Treatment for Advanced Prostatic Cancer | Q70149943 | ||
| The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue | Q70434841 | ||
| [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer] | Q70500492 | ||
| Antagonistic effect of androgen on prostatic cell death | Q70629225 | ||
| Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation | Q70742310 | ||
| Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer | Q71932646 | ||
| Testosterone in Human Plasma | Q72562425 | ||
| Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer | Q73251631 | ||
| Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making | Q73290328 | ||
| Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer | Q28375064 | ||
| Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. | Q31060097 | ||
| Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center | Q32082335 | ||
| Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 | ||
| Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer | Q33674981 | ||
| Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis | Q33879512 | ||
| Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients | Q33942798 | ||
| The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression | Q34045475 | ||
| Transsphenoidal hypophysectomy in the treatment of metastatic breast and prostate carcinoma | Q34052328 | ||
| Cost-effectiveness of androgen suppression therapies in advanced prostate cancer | Q34073620 | ||
| The case for neoadjuvant androgen suppression before radiation therapy | Q34076093 | ||
| Clinical pharmacokinetics of depot leuprorelin | Q34135364 | ||
| Hormonal therapy: historical perspective to future directions | Q34187285 | ||
| Leuprolide versus diethylstilbestrol for metastatic prostate cancer | Q34260348 | ||
| Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients | Q34596863 | ||
| Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer | Q34617931 | ||
| Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer | Q35206784 | ||
| Implantation of radioactive material into the pituitary for the control of prostatic cancer: an interim review | Q35250990 | ||
| Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant | Q35620881 | ||
| Development of prostate cancer treatment: the good news | Q35638458 | ||
| Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer | Q36091195 | ||
| The current role of chemotherapy in metastatic hormone-refractory prostate cancer | Q36122672 | ||
| QUANTITATIVE STUDIES OF PROSTATIC SECRETION : II. THE EFFECT OF CASTRATION AND OF ESTROGEN INJECTION ON THE NORMAL AND ON THE HYPERPLASTIC PROSTATE GLANDS OF DOGS. | Q36259858 | ||
| Pharmacological studies on androgen suppression in therapy of prostate carcinoma | Q36445837 | ||
| Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective | Q36456013 | ||
| Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer | Q36473341 | ||
| Maximum androgen blockade: a clinical update. | Q36598408 | ||
| A critical review of maximal androgen blockade for advanced prostate cancer. | Q36598422 | ||
| The case for secondary hormonal therapies in the chemotherapy age. | Q36644345 | ||
| Early effects of pharmacological androgen deprivation in human prostate cancer. | Q36709642 | ||
| Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders | Q36972988 | ||
| Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone | Q37605687 | ||
| Indications for use of ketoconazole in management of metastatic prostate cancer | Q38000258 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | leuprolide | Q907160 |
| P304 | page(s) | 513-526 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Leuprorelin depot injection: patient considerations in the management of prostatic cancer | |
| P478 | volume | 4 |
| Q84127846 | Intermittent androgen deprivation therapy: redefining the standard of care? |
| Q36975113 | Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation |
| Q84622973 | Leuprolide acetate, a GnRH agonist, improves experimental autoimmune encephalomyelitis: a possible therapy for multiple sclerosis |
| Q64118316 | Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye |
| Q92177866 | Long-Acting Injectable Statins-Is It Time for a Paradigm Shift? |
| Q37230483 | Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer |
| Q35577254 | Sustained-release delivery of octreotide from biodegradable polymeric microspheres |
Search more.